Harnessing Coordinated CD4⁺ and CD8⁺ T-Cell Immunity for Virus-Specific Adoptive Immunotherapy in Africa
Keywords:
Virus-specific T cells, Adoptive immunotherapy, Emerging viral infections, CD4⁺ T cells, CD8⁺ T cells, HLA, AfricaAbstract
Virus-specific T-cell (VST) therapy has developed principally for persistent or reactivating viral infections in immunocompromised patients, with the strongest clinical experience involving cytomegalovirus, Epstein–Barr virus, human adenovirus, BK polyomavirus and human herpesvirus 6. Whether this approach can be extended to emerging and re-emerging viral infections remains less certain. Evidence that virus-specific CD4⁺ and CD8⁺ T cells contribute to natural or vaccine-induced protection provides a biological basis for therapeutic development but does not establish the efficacy of adoptively transferred VSTs. This distinction is particularly important for viruses of relevance to Africa, including Ebola virus, Lassa virus, Marburg virus, dengue virus, chikungunya virus, Rift Valley fever virus and mpox virus. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) provides clinical proof-of-concept that rapidly developed, partially HLA-matched or banked virus-reactive T-cell products can be administered against a newly emerging pathogen. Experimental adoptive transfer studies provide additional evidence for selected pathogens, including Ebola virus, whereas other emerging viruses remain supported mainly by human immunological, epitope or preclinical data. Translation to African populations will require definition of protective viral targets, population-relevant HLA restrictions, viral sequence conservation, manufacturing feasibility and clinical indications in which cellular therapy offers a clear advantage. This review examines the evidence required to move from antiviral T-cell immunity to therapeutic VST development and proposes a framework for evaluating emerging and re-emerging viral infections as future VST targets in Africa.
Downloads
Published
How to Cite
Issue
Section
Copyright (c) 2026 Caroline MANGARE
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All content published in the Journal of Clinical Care and Medical Advancement is licensed under the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license ensures that published work is freely accessible and allows for the sharing and adaptation of the content under the following conditions:
1. Attribution
- Users must provide appropriate credit to the original author(s) and the journal. This includes citing the article title, author names, journal name, volume/issue, and DOI (if available).
- Attribution must not imply endorsement by the author(s) or the journal unless explicitly agreed upon.
2. NonCommercial Use
- Content may not be used for commercial purposes. Any use that involves monetary gain, commercial distribution, or resale of the material is strictly prohibited without prior written permission from the journal or the copyright holder(s).
3. Adaptations and Derivatives
- Users are allowed to create adaptations, modifications, and derivative works based on the content, provided they comply with the attribution and non-commercial terms.
- Any adaptations must indicate that changes were made to the original work, and the original author(s) must still be credited appropriately.
4. No Additional Restrictions
- Users are not permitted to impose legal or technological restrictions on others that prevent them from exercising the rights granted under this license.
5. Exceptions and Permissions
- For uses beyond the scope of the CC BY-NC 4.0 license, such as commercial use or sublicensing, explicit permission must be obtained from the journal or the original author(s).
- Authors retain the copyright of their works and may enter into separate agreements for non-exclusive distribution, provided that the original publication in this journal is acknowledged.
6. License Notice
- All articles will include a clear notice indicating that they are published under the CC BY-NC 4.0 license. Example:
“This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0/.”
7. Author Rights and Obligations
- Authors retain the copyright to their works but grant the journal the right to publish and distribute the content under the CC BY-NC 4.0 license.
- Authors must ensure that their submissions do not infringe on the copyright of third parties and that all necessary permissions are obtained for any copyrighted material included in their work.
